Clinical Trial

Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to look at genes and determine how they interact with each other to find changes that could explain why some people's immune systems may respond to blood transfusions. This response is called an alloimmune response. We strongly believe that when someone has an alloimmune response, it is caused by changes in their genes. We plan to compare changes in the genes of individuals that develop red blood cell alloimmunization after blood transfusions with those that do not develop alloimmunization. This may help us to create more targeted therapeutic interventions, which may improve the health of alloimmune responders.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-04-24; most recent amendment 2026-05-23.
Status change: Not Yet Recruiting → Recruiting 2025-05-21
Trial Details
NCT Number NCT06944067
Lead Sponsor National Human Genome Research Institute (NHGRI)
Conditions Sickle Cell Disease
Enrollment 50 participants
Start Date 2025-06-24
Primary Completion 2030-04-10 (estimated)
Study Completion 2030-04-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-27